
McKesson to Pay $190 Million to Resolve False-Claims Allegations
In a news release, the U.S. Justice Department said that states can separately negotiate resolutions with McKesson pertaining to claims based on the states' shares of Medicaid overpayments.
Story in progress.
Read this story:
Source: ModernHealthcare.com
McKesson Corp., a San Francisco-based drug wholesaler and health information technology provider, will pay the U.S. more than $190 million to resolve claims it reported inflated prices for several prescription drugs, causing Medicaid to overpay for the drugs.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.